The firm, which notes that Vera is conducting the Phase 3 ORIGIN 3 study of 150 mg atacicept in patients with IgAN while utilizing at-home administration with once-weekly dosing, reiterates a Buy ...
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Award-winning broadcast journalist and nag-iisang Igan ng Bayan Arnold Clavio (center) reaffirmed his loyalty as a Kapuso by renewing his exclusive contract with GMA Network on December 3.
Hosted on MSN3mon
Arnold Clavio gives moving speech as he renews contract with GMA Network: ‘Renewed human being po ako’The program managers whom Igan worked with also showed their support, namely Mon Torres, Amy Sy-Gueverra, JC Rubio, and Sarah Gulle. Connie Sison, GMA broadcaster and Igan’s co-host on “One on ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European ...
Despite potential volatility ahead of the readouts, “We continue to recommend the stock as the profile is greatly derisked & will benefit from first-ish mover advantage in IgAN, a field ...
The company has received FDA Breakthrough Therapy Designation for atacicept in IgAN, which could signify a substantial improvement over existing therapies. Vera reported a net loss of $152.1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback